These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
4. Gene expression classification of colon cancer into molecular subtypes: characterization, validation, and prognostic value. Marisa L; de Reyniès A; Duval A; Selves J; Gaub MP; Vescovo L; Etienne-Grimaldi MC; Schiappa R; Guenot D; Ayadi M; Kirzin S; Chazal M; Fléjou JF; Benchimol D; Berger A; Lagarde A; Pencreach E; Piard F; Elias D; Parc Y; Olschwang S; Milano G; Laurent-Puig P; Boige V PLoS Med; 2013; 10(5):e1001453. PubMed ID: 23700391 [TBL] [Abstract][Full Text] [Related]
5. A novel mesenchymal-associated transcriptomic signature for risk-stratification and therapeutic response prediction in colorectal cancer. Matsuyama T; Kandimalla R; Ishikawa T; Takahashi N; Yamada Y; Yasuno M; Kinugasa Y; Hansen TF; Fakih M; Uetake H; Győrffy B; Goel A Int J Cancer; 2020 Dec; 147(11):3250-3261. PubMed ID: 32657428 [TBL] [Abstract][Full Text] [Related]
6. Interconnectivity between molecular subtypes and tumor stage in colorectal cancer. Coebergh van den Braak RRJ; Ten Hoorn S; Sieuwerts AM; Tuynman JB; Smid M; Wilting SM; Martens JWM; Punt CJA; Foekens JA; Medema JP; IJzermans JNM; Vermeulen L BMC Cancer; 2020 Sep; 20(1):850. PubMed ID: 32887573 [TBL] [Abstract][Full Text] [Related]
7. A Clinically Applicable Gene-Expression Classifier Reveals Intrinsic and Extrinsic Contributions to Consensus Molecular Subtypes in Primary and Metastatic Colon Cancer. Piskol R; Huw L; Sergin I; Kljin C; Modrusan Z; Kim D; Kljavin N; Tam R; Patel R; Burton J; Penuel E; Qu X; Koeppen H; Sumiyoshi T; de Sauvage F; Lackner MR; de Sousa E Melo F; Kabbarah O Clin Cancer Res; 2019 Jul; 25(14):4431-4442. PubMed ID: 31004000 [TBL] [Abstract][Full Text] [Related]
8. Transcriptomic and proteomic intra-tumor heterogeneity of colorectal cancer varies depending on tumor location within the colorectum. Árnadóttir SS; Mattesen TB; Vang S; Madsen MR; Madsen AH; Birkbak NJ; Bramsen JB; Andersen CL PLoS One; 2020; 15(12):e0241148. PubMed ID: 33332369 [TBL] [Abstract][Full Text] [Related]
9. HER2 overexpression and amplification as a potential therapeutic target in colorectal cancer: analysis of 3256 patients enrolled in the QUASAR, FOCUS and PICCOLO colorectal cancer trials. Richman SD; Southward K; Chambers P; Cross D; Barrett J; Hemmings G; Taylor M; Wood H; Hutchins G; Foster JM; Oumie A; Spink KG; Brown SR; Jones M; Kerr D; Handley K; Gray R; Seymour M; Quirke P J Pathol; 2016 Mar; 238(4):562-70. PubMed ID: 26690310 [TBL] [Abstract][Full Text] [Related]
11. Challenging the Cancer Molecular Stratification Dogma: Intratumoral Heterogeneity Undermines Consensus Molecular Subtypes and Potential Diagnostic Value in Colorectal Cancer. Dunne PD; McArt DG; Bradley CA; O'Reilly PG; Barrett HL; Cummins R; O'Grady T; Arthur K; Loughrey MB; Allen WL; McDade SS; Waugh DJ; Hamilton PW; Longley DB; Kay EW; Johnston PG; Lawler M; Salto-Tellez M; Van Schaeybroeck S Clin Cancer Res; 2016 Aug; 22(16):4095-104. PubMed ID: 27151745 [TBL] [Abstract][Full Text] [Related]
12. CMS-dependent prognostic impact of KRAS and BRAFV600E mutations in primary colorectal cancer. Smeby J; Sveen A; Merok MA; Danielsen SA; Eilertsen IA; Guren MG; Dienstmann R; Nesbakken A; Lothe RA Ann Oncol; 2018 May; 29(5):1227-1234. PubMed ID: 29518181 [TBL] [Abstract][Full Text] [Related]
13. Bone morphogenetic protein and Notch signalling crosstalk in poor-prognosis, mesenchymal-subtype colorectal cancer. Irshad S; Bansal M; Guarnieri P; Davis H; Al Haj Zen A; Baran B; Pinna CMA; Rahman H; Biswas S; Bardella C; Jeffery R; Wang LM; East JE; Tomlinson I; Lewis A; Leedham SJ J Pathol; 2017 Jun; 242(2):178-192. PubMed ID: 28299802 [TBL] [Abstract][Full Text] [Related]
17. Correlation of Immunological and Histopathological Features with Gene Expression-Based Classifiers in Colon Cancer Patients. van de Weerd S; Smit MA; Roelands J; Mesker WE; Bedognetti D; Kuppen PJK; Putter H; Tollenaar RAEM; Roodhart JML; Hendrickx W; Medema JP; van Krieken JHJM Int J Mol Sci; 2022 Oct; 23(20):. PubMed ID: 36293565 [TBL] [Abstract][Full Text] [Related]
18. Recurrence risk assessment for stage III colorectal cancer based on five methylation biomarkers in plasma cell-free DNA. Wang W; Zhu X; Zhang X; Lei C; Zeng Z; Lan X; Cui W; Wang F; Xu S; Zhou J; Wu X; Deng H; Li X; Fan J; Ding Y; Huang Z; Liang L J Pathol; 2023 Apr; 259(4):376-387. PubMed ID: 36573552 [TBL] [Abstract][Full Text] [Related]
19. Overexpression of TSPAN8 in consensus molecular subtype 3 colorectal cancer. Suwatthanarak T; Tanjak P; Chaiboonchoe A; Acharayothin O; Thanormjit K; Chanthercrob J; Suwatthanarak T; Niyomchan A; Tanaka M; Okochi M; Pongpaibul A; Chalermwai WV; Trakarnsanga A; Methasate A; Pithukpakorn M; Chinswangwatanakul V Exp Mol Pathol; 2024 Jun; 137():104911. PubMed ID: 38861838 [TBL] [Abstract][Full Text] [Related]
20. Technical differences between sequencing and microarray platforms impact transcriptomic subtyping of colorectal cancer. Eilertsen IA; Moosavi SH; Strømme JM; Nesbakken A; Johannessen B; Lothe RA; Sveen A Cancer Lett; 2020 Jan; 469():246-255. PubMed ID: 31678167 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]